Laxmi Dental
- Market cap
- ₹ 946 Cr.
- P/E
- 26.9x
- P/B
- 3.99x
- 52-week range
- 155.88 – 344.8
- ROE
- 15%
- ROCE
- 15%
- Dividend yield
- 0%
- Debt / equity
- 0.05
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
Laxmi Dental Limited is an end-to-end integrated dental products company. Its segments include Laboratory Business, Aligners Business, and Other Business. The Laboratory Business consists of dental prosthesis, such as metal free crowns and bridges, porcelain fused to metal (PFM) crowns and bridge dentures. The Aligners Business consists of dental aligners, retainers, raw materials for aligners, sport guards, night guards, sleep apnea devices. The Other Business consists of dental distribution products used in dental laboratories, dental clinical services and dental educational courses. It manufactures and supplies thermoforming sheets, thermoforming machines, dental consumables, biocompatible resins for 3D printing under its brand Taglus tailored for manufacturing of clear aligners. It offers a range of pediatric products, including pre-formed branded pediatric crowns, silver diamide fluoride (SDF), space maintainers, fissure sealant, reinforced splint and mineral trioxide aggregate.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Laxmi Dental against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)26.9 against a typical 26.9: in line than most peers (1st = cheapest).13th of 25
- Sales growth+13.6% against a typical +21.5% from a year earlier.14th of 18
- Profit growth+25% against a typical +13.4% from a year earlier.6th of 16
- Share price, 3 months−16.8% against a typical −7.9%.17th of 23
- Size₹ 945.8 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).6th of 24
Latest announcements
Exchange filings and their impact on the company.
- 21 Oct 2026Effect(s) on listed entity due to changed regulatory framework applicableMedium impactPositivePrice −0.7% on 22 OctUS subsidiary gets Rs 5.9 cr tariff refund in one-off profit boost.
Laxmi Dental said its US subsidiary, Laxmi Dental Lab USA Inc, has received a tariff refund of USD 0.63 million, about Rs 5.92 crore, from US Customs and Border Protection. The refund follows US Supreme Court directives to return excess tariffs collected from importers. It is a one-time cash inflow that will boost other income and profit, with no change to core dental business operations.
- IPO money re-routed to a new Rs 48 cr dental lab and aligner plant, with Rs 30 cr to be spent in next year.
Laxmi Dental's Q2 FY27 monitoring report from ICRA says IPO proceeds use is on track with no material deviation. Shareholders approved a change to use about Rs 48.1 crore of unspent machinery budget to buy land, build a dental laboratory and aligner plant and equip it. About Rs 47.8 crore remains parked in ICICI Bank fixed deposits earning 6.25-7.05% pending FY27-FY28 construction.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 21 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 10 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 26 May 2025 | Financial Results/Other business matters | To consider and approve the audited financial results (Standalone and Consolidated) for the quarter and year ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 55 | 60 | 57 | 62 | 61 | 66 | 72 | 66 | 74 | 75 |
| Expenses | 44 | 43 | 46 | 48 | 52 | 51 | 54 | 61 | 59 | 60 | 60 |
| Operating Profit | 4 | 12 | 14 | 9 | 10 | 10 | 12 | 11 | 7 | 14 | 14 |
| OPM % | 8% | 21% | 23% | 15% | 16% | 16% | 18% | 15% | 11% | 18% | 19% |
| Other Income | 0 | 0 | 6 | 1 | 1 | 2 | 2 | 2 | −4 | 2 | 2 |
| Interest | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | −1 | 7 | 16 | 5 | 5 | 6 | 10 | 9 | −1 | 11 | 12 |
| Tax % | −140% | 16% | 11% | 23% | 23% | 41% | 24% | 20% | −175% | 4% | 21% |
| Net Profit | 2 | 8 | 17 | 6 | 5 | 4 | 8 | 9 | 2 | 10 | 10 |
| EPS in Rs | 74.05 | 243.91 | 6.04 | 2.12 | 0.93 | 0.78 | 1.53 | 1.55 | 0.36 | 1.83 | 1.87 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 25%
- 3 Years
- 20%
- TTM
- 17%
- 10 Years
- —
- 5 Years
- 103%
- 3 Years
- 124%
- TTM
- 50%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 18%
- 3 Years
- 23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Laxmi Dental | ₹ 181.00 | ₹ 946 Cr. | 26.9x | 4x | 15% | — |
| Lenskart Solutions | ₹ 627.55 | ₹ 1,08,959 Cr. | 181x | 10.7x | 6.7% | 5.7% |
| Poly Medicure | ₹ 1,446.80 | ₹ 14,582 Cr. | 52.1x | 5.5x | 11% | 17.1% |
| One Global Service Provider | ₹ 372.00 | ₹ 721 Cr. | 17x | 8.3x | 65.2% | 14% |
| Mallcom (India) | ₹ 909.00 | ₹ 567 Cr. | 21.9x | 2.1x | 9.7% | 5.6% |
| Hemant Surgical Industries | ₹ 570.00 | ₹ 829 Cr. | 26x | 3.7x | 18.1% | 7.9% |
Management
- Rajesh Vrajlal Khakhar
- Whole-Time Chairman of the Board
- Sameer Kamlesh Merchant
- Chief Executive Officer, Managing Director, Executive Director
- Dharmesh Dattani
- Chief Financial Officer
Prices are delayed and for information only. Nothing on this page is investment advice.